Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic ...

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says ...

The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The ...

Smile 2 is now available to watch on digital and streaming platforms, introducing even more people to its shocking ending. But while it's shocking to us, writer/director Parker Finn always felt it ...

Oxford, UK-based clinical-stage biotech Theolytics today announced the appointment of biotechnology industry leader David Apelian as chief executive (CEO). Dr Apelian brings 25 years of leadership ...

Chinese biotech RemeGen has presented results from a Phase III trial of disitamab vedotin, an HER2-targeted antibody-drug conjugate (ADC), at the San Antonio Breast Cancer Symposium. The Yantai-based ...

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Maryam Sarraf Yazdy, U.S. Food and Drug Administration, WO22 Room 2169, ...

In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs.

Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced ...

Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced ...